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associated with cirrhosis and the treatment of HCC must 
take into account the presence and stage of chronic 
liver disease. The major treatment modalities of HCC 
include: (1) surgical resection; (2) liver transplantation; 
(3) local ablation therapy; (4) transarterial locoregional 
treatment; and (5) systemic treatment. Among these, 
resection, liver transplantation and ablation therapy for 
small HCC are considered as curative treatment. Portal 
vein embolisation and the associating liver partition 
with portal vein ligation for staged hepatectomy may 
reduce dropout in patients with marginally resectable 
disease but the midterm and long-term results are still 
to be confirmed. Patient selection for the best treatment 
modality is the key to success of treatment of HCC. The 
purpose of current review is to provide a description 
of the current advances in diagnosis, staging, pre-
operative liver function assessment and treatment 
options for patients with HCC in the east.
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Core tip: Management of hepatocellular carcinoma 
(HCC) has changed significantly over the past several 
decades. However, the management of patients has 
yet to be standardized. As a result of high prevalence 
of hepatitis B infection in Asia, the experience of the 
East helped to develop a more aggressive management 
algorithm. There has been a lot of advancement in 
terms of diagnosis, management algorithm, staging 
and treatment methods. This paper will give an update 
on the management of HCC in the eastern population.
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Abstract
Hepatocellular carcinoma (HCC) is one of the com-
monest malignant tumours in the East. Although the 
management of HCC in the West is mainly based 
on the Barcelona Clinic for Liver Cancer staging, it is 
considered too conservative by Asian countries where 
the number of HCC patients is huge. Scientific and 
clinical advances were made in aspects of diagnosis, 
staging, and treatment of HCC. HCC is well known to be 
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Update in management of hepatocellular carcinoma in 
Eastern population
INTRODUCTION
Hepatocellular carcinoma (HCC) is the sixth most 
common cancer and the third most common cause of 
cancer-related deaths worldwide[1]. Because of the high 
prevalence of hepatitis B virus infection[2], countries in 
Eastern and Southeast Asia have the highest incidence 
of HCC in the world[3]. However, the management of 
patients with HCC has yet to be standardized in aspects 
of diagnosis, staging and treatment. Although the 
management of HCC in the West is mainly based on 
the Barcelona Clinic for Liver Cancer (BCLC) staging[4], 
it is considered too conservative by Asian countries. 
With advancement in diagnosis, staging and treatment, 
management algorithm of HCC is further modified. 
The aim of the present review is to provide a summary 
and update for clinical practice to determine the most 
appropriate treatment for HCC patients.
DIagNOsIs
With clinical suspicion or screening, the diagnosis of 
HCC is based on laboratory tests, radiological imaging 
and, where appropriate, liver biopsy. The American 
Association for the Study of Liver Disease (AASLD)[5] 
diagnostic algorithm is widely used for surveillance and 
diagnosis. In short, nodules less than 1 cm which cannot 
be precisely characterised in ultrasound are subjected 
to interval scan. Nodules detected at ultrasound with 
diameter greater than 10 mm are further investigated 
with contrast computed tomography (CT) or magnetic 
resonance imaging (MRI). Nodules with typical feature 
of arterial enhancement and porto-venous washout are 
treated as HCC[6]. 
MRI was reported to have a higher sensitivity 
compared with CT[7]. In cases in which the diagnosis 
is uncertain, a serum alpha-fetoprotein (AFP) level > 
400 ng/mL has a high positive predictive value[8]. The 
sensitivity of MRI scan with contrast ranged from 33% 
to 61.7% according to different studies targeted for 
lesions smaller than 2 cm[9]. In order to provide better 
results, the use of gadoxetic acid-enhanced MRI as an 
investigation tool has been widely investigated. The 
initial result of Primovist base MRI showed an improved 
sensitivity from 64% to 86%[10]. 
Dual tracer positron emission tomography (PET)-
CT with 11C-acetate and 18F-fludeoxyglucose (FDG) 
markers was reported to have high sensitivity and 
specificity for diagnosis of HCC. The liver helps to 
maintain glucose homeostasis[11] and there are a variety 
of different levels of glucose-6-phosphatase activity 
and glucose transporters in HCC[12-14]. It was reported 
that well-differentiated HCCs preferentially accumulate 
11C-acetate[15] and poorly differentiated tumours tend 
to preferentially accumulate FDG. Ho et al[15] found 
dual-tracer PET-CT to have a sensitivity of 98% and a 
specificity of 86% which were considered significantly 
improved to other imaging modality alone[16]. Apart from 
higher sensitivity, the 18F-FDG tracer played an additional 
role in providing prognostic indicators to lesion with 
poorly differentiated HCCs[17]. 
Tumour biopsy can be done if non-invasive studies 
failed to characterize the lesion.
Diagnostic strategies vary between guidelines, e.g., 
European Association for the Study of the Liver[18] and 
AASLD[19], but the process is generally determined by the 
size of liver nodules. The recently developed technique of 
dual-tracer PET-CT may help for atypical lesions.
Knowing that in around 30% patients with HCC, the 
AFP level remains normal, a high index of suspicion is 
crucial particularly in area like Southeast Asia where 
hepatitis B is endemic.
sTagINg
Cancer staging is the process of determining the extent 
to which a cancer has developed and help to select the 
most appropriate treatment for any particular stage 
of disease[20]. The prognosis and treatment outcome 
of HCC is related with tumour staging, liver function 
and patient’s physical status[19]. The BCLC staging 
system[21] and the newly developed Hong Kong Liver 
Cancer (HKLC) staging system[22] addresses all these 
factors. A number of other staging systems for HCC 
are available, e.g., TNM system[23], The Cancer of Liver 
Italian Program[24], Okuda staging system[25], etc., but 
they only included some of these related factors.
In Eastern Asia where the highest incidence rates (> 
20/100000 per year) of HCC occur, hepatitis B infection 
accounts for 70% of HCC cases[26]. While in Europe and 
North America where lower incidence rates (< 5/100000 
per year) of HCC, hepatitis C and alcohol are the major 
etiologies. In view of the difference in epidemiologic and 
clinical characteristics, different therapeutic approaches 
were developed in the East and West centres[4,22,27,28]. 
Indeed, until recently, studies comparing treatment 
outcomes of eastern and western experiences with HCC 
are lacking.
The BCLC is widely used and quoted in the literature. 
However, it was derived from analysis of cohorts involving 
mainly Caucasian and may work better in Caucasian 
populations[29-31]. In Asia, more aggressive treatment 
options were recommended especially for BCLC 
intermediate- and advanced-stage patients[32,33]. The 
differences of treatment algorithms of APASL guideline, 
Japan Society of Hepatology guidelines, HKLC and BCLC 
staging systems were summarized in Table 1. These 
guidelines are followed by the corresponding community. 
However, the comparison between treatment outcomes 
following different algorithms is subjected to future study.
Recently, a new HCC classification system has been 
proposed in Hong Kong in order to provide a better 
guideline in area where the proportion of HCC and 
cirrhosis is higher. Although BCLC staging had fairly 
good discriminatory power in the test set, HKLC staging 
was significantly better than BCLC staging statistically 
in stratifying HCC patients into different prognostic 
groups. Overall, our HKLC treatment algorithm yielded 
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better survival outcomes when compared with the BCLC 
treatment algorithm, as evidenced by the hypothetical 
survival curves. The effectiveness of the HKLC treat-
ment guidelines vs the BCLC treatment schedule has 
been clearly observed in the aforementioned patient 
subsets.The Hong Kong group showed better survival 
outcomes can be achieved if these patients received a 
more radical approach of therapies[22]. 
LIveR ReseCTION
Pre-operative patient evaluation and case selection
Liver resection follows the basic principle of surgery. 
The patients have to be fully assessed for performance 
status and anaesthesiology fitness together with the 
tumour status including the tumour locations. Although 
BCLC criteria do not suggest liver resection for Stage 
B disease which comprise of tumour larger than 5 cm 
in size, many centres in Asia does not consider tumour 
size as an absolute contraindication to surgery. In many 
of the Asian centres including Hong Kong will consider 
hepatectomy for HCC as long as there is no extrahepatic 
disease or multifocal diffuse disease[34]. 
The other factor that affects liver resection is liver 
function reserve assessment. More than 80% of 
patients with HCC are hepatitis B carrier and around 
half of these patients have different degree of cirrhosis. 
It is important that patients with poor liver function 
reserve should not receive excessive removal of liver 
parenchyma in order to avoid postoperative liver failure. 
In general only selected patients with Child A cirrhosis 
should be considered for major hepatectomy[35]. In 
addition, several adjuvant investigations are crucial as 
part of preoperative liver function assessment.
Indocyanine green clearance test: Indocyanine 
green (ICG) is a dye which binds completely to albumin 
and β-lipoprotein and is exclusively removed by the 
liver and excreted unchanged in bile without any 
entero-hepatic circulation[36]. The ICG retention at 
15 min (ICGR-15) can be measured with serial blood 
sampling or pulse spectrophotometry methods[37,38]. 
ICGR-15 is about 10% in normal person. It was shown 
to be correlated with hospital mortality so that it was 
recommended that ICGR-15 for a safe major and minor 
hepatectomy are 14% and 22%, respectively[35]. 
Imaging-based volumetry: Liver volumetry is most 
commonly estimated with 3-D volume CT calculation[39]. 
The post-operative residual liver volume [future liver 
remnant (FLR)] can be calculated based on cross-
imaging techniques, on each slice FLR are outlined and 
integrated[40]. The estimated standard liver volume (ESLV) 
can be calculated with a formula based upon regression 
analysis of normal population in which body weight and 
height are included[41,42]. The FLR-to-ESLV ratio was 
shown to have inverse correlation with increasing risk for 
post-hepatectomy liver failure and post-operative death.
The critical residual liver volume for patients with 
normal liver had been reported to be 20%-30% according 
to different authors[43-47]. In general FLR > 20% is 
considered safe and with low risk of postoperative hepatic 
dysfunction[46]. However, most HCCs are associated with 
cirrhotic liver or diseased liver. The safety of surgical 
resection is greatly determined by the degree of liver 
dysfunction due to the underlying liver disease[48,49]. In 
literature, it is generally accepted that the FLR required is 
considerably larger than those with a normal liver, given 
the impaired baseline function of hepatocytes. It was 
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Table 1  Comparison between treatment algorithms of Asian guidelines for hepatocellular carcinoma and Barcelona Clinic for Liver 
Cancer staging system
The HKLC staging system[22] The JSH guidelines[28] The APASL guidelines[27] The BCLC staging system[4]
Parameters included Performance status Liver function Liver function Performance status
Liver function Vascular invasion/metastases Vascular invasion/metastases Liver function
Vascular invasion/metastases Tumour staging Tumour staging Vascular invasion/metastases
Tumour staging Tumour staging
Definition of vascular 
invasion
Extrahepatic vascular invasion: 
main portal vein and inferior 
vena cava invasion
Portal vein invasion 
categorized into Vp1-4
Invasion to hepatic/portal vein 
branches
Portal vein invasion considered 
as advanced stage 
Definition of tumour 
staging
3 categories: early, intermediate, 
locally advanced
Categories according to 
number and size
3 categories: resectable, non-
resectable within Milan criteria, 
non-resectable exceeding Milan 
criteria
5 categories: very early, early, 
intermediate, advanced and 
terminal stages
Criteria for resection Early tumour, Child A/B and 
intermediate tumour Child A
Any resectable HCC Resection can be considered for 
number ≥ 4 although TACE is 
the first choice
Only solitary HCC or 3 
nodules < 3 cm are subjected to 
resection
Left or right portal vein invasion 
can be considered for resection
HCC with portal invasion at 
second or more peripheral 
portal branch can be considered 
for resection
HKLC: Hong Kong Liver Cancer; JSH: Japan Society of Hepatology; BCLC: Barcelona Clinic for Liver Cancer; HCC: Hepatocellular carcinoma; TACE: 
Transarterial chemoembolization; APASL: The Asian Pacific Association for the Study of the Liver.
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The mean period between PVE and hepatectomy was 
reported to be 37 d (range: 21-84 d) and the mean 
hypertrophy rate of FLR was reported to be 38%[64]. 
On the other hand, approximately 10% of patient 
cannot have the surgery performed because of failure 
of PVE, inadequate hypertrophy, complication leading to 
unresectability and local tumour progression[64]. 
The associating liver partition with portal vein 
ligation for staged hepatectomy approach associates in-
situ splitting to portal vein ligation. It has been shown to 
be effective for the induction of rapid FLR hypertrophy 
so as to improve the respectability[65]. It was proposed 
that the portal flow deprivation in future resected 
liver and accentuated inflammatory response induces 
faster regeneration compared to traditional portal vein 
occlusion methods[66]. Therefore, the approach may 
reduce dropout in patients with marginally resectable 
disease but the midterm and long-term results are still 
to be confirmed.
LOCaL abLaTION TheRapy
Local ablation therapy is used in patients with early-stage 
HCC who are not suitable for surgical resection[67]. The 
currently preferred methods included radiofrequency 
ablation, microwave ablation and High Intensity Focused 
Ultrasound (HIFU).
Radiofrequency ablation (RFA) utilises alternating 
electrical current with a frequency 200 k-20 MHz in the 
range of radio-waves and causes coagulative necrosis 
and tissue desiccation[68]. RFA has largely replaced 
percutaneous ethanol injection because it produces 
better recurrence-free survival and requires fewer 
treatment sessions[69]. RFA can be performed percuta-
neously under image guidance or during surgery guided 
by intraoperative ultrasound. Complete ablation of small 
lesions is possible in more than 90% of cases[70]. The 
overall 5-year survival rates between 33% and 55% in 
selected series[71]. and lower mortality and morbidity 
rates were reported[72]. Therefore, RFA is considered as 
an alternative to resection especially for small HCC. Three
randomized controlled trials are available comparing 
hepatic resection and RFA[73-75]. Although they reported 
conflicting results, it seems reasonable to offer RFA to 
very small HCC (< 2 cm) with no technical contrain-
dications[76]. Except for the use of RFA on solitary 
tumours, multifocal tumour prevalence was also high in 
ablated patients. Rather than competing techniques, RFA 
can sometimes be combined with hepatectomy tailored 
to suit the anatomical condition.
Microwave ablation (MWA) utilizes electromagnetic 
methods for tumour destruction with frequency ≥ 
900 MHz[77]. Microwave ablation can achieve higher 
temperature[78] shorter ablation time[78-81] and does not 
require the placement of ground pads. Several studies[82-84] 
showed that the local tumour control, complications and 
long-term survival were equivalent for RFA and MWA in 
the treatment of HCC.
HIFU is a non-invasive modality that uses an 
reported that FLR > 30%-50% are considered safe for 
patients with diseased liver[50-52]. 
sURgICaL ReseCTION
The aim of hepatectomy is to obtain radical resection 
with adequate liver reserve. When performed in 
specialised centres, hepatectomy can achieve 5-year 
survival above 50%[53]. In the more aggressive APASL 
guideline, the only contraindication to resection is the 
presence of distant metastases, main portal vein or 
inferior vena cava involvement[27]. Even for advanced 
tumour > 5 cm or multinodular (> 3 nodules), a 5-year 
survival of 39% was reported[34] comparing with 5-year 
survival for transarterial chemoembolisation (TACE) was 
only 6%-19%[54-56]. While following the BCLC protocol, 
patients with multinodular tumours would be excluded 
for surgical resection. Vascular invasion was associated 
with poor prognosis in untreated patients[4]. As liver 
transplant is contraindicated and TACE or systemic 
therapy is ineffective, surgical resection remains the 
only possible curative treatment in patients with good 
liver reserve. Five years survival of patients with portal 
vein thrombus underwent liver resection was reported 
to be 26%-42%[57,58]. 
Conventionally, liver resection is mainly carried 
by open approach. In recent years, laparoscopic liver 
resection for cancer has gaining popularity and many 
results showed that minimally invasive approach can 
produce equally good oncological outcome even in 
patients with liver cirrhosis for minor hepatectomy[59]. 
Laparoscopic hepatectomy was initially adopted 
to treat peripheral, benign tumour in a normal liver. 
Multiple series showed the feasibility of its application 
for HCC[60]. However, patient selection needs to be 
careful. Some technical manoeuvres frequently used in 
open hepatectomy, such as organ mobilization, control 
of vascular inflow, and hanging manoeuvre are difficult 
in laparoscopic setting and controlling haemorrhage is 
also difficult. The Louisville consensus suggested that 
the laparoscopic approach to left lateral sectionectomy 
should be considered standard practice[61]. 
pORTaL veIN embOLIsaTION aND The 
assOCIaTINg LIveR paRTITION wITh 
pORTaL veIN LIgaTION fOR sTageD 
hepaTeCTOmy
Hepatectomy is the only option for long term survival for 
many patients with HCC. However, the resectability rate 
for HCC is approximately 20%-30% with normal liver, 
and further reduced in patients with cirrhotic liver[62]. 
Portal vein embolisation (PVE) is one of the methods to 
stimulate growth of the FLR. Kinoshita et al[63] reported 
the first preoperative PVE in 1986. Various techniques 
for PVE were reported and percutaneous transhepatic 
technique has become the standard technique for PVE. 
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extracorporeal source of focused ultrasound energy[85]. 
It is able to induce coagulative necrosis in selected 
tissues. HIFU ablation utilizes a unique frequency 
of ultrasound wave of 0.8 to 3.5 MHz, which can be 
focused at a distance from the therapeutic transducer. 
The accumulated energy at the focused region induces 
necrosis of the target lesion by elevating the tissue 
temperature to above 60 ℃. Temperature outside the 
focus point remains static as particle oscillation remains 
minimal. As ultrasound energy travels much better in 
water than in air, the presence of ascites in HCC patients 
actually facilitates energy propagation to the target HCC. 
Passage of energy without the puncture of a physical 
instrument and its superior performance in patients 
with ascites give HIFU ablation superiority over other 
treatment modalities for HCC. Initial results of HIFU 
ablation in the management of HCC were promising with 
a complete ablation rate of 28.5% to 68% for single 
treatment[86]. This non-invasive approaches has shown 
to produce very little collateral damage to the normal 
liver parenchymal in patients with cirrhosis and is well 
tolerated even in selected patients with Child Pugh C 
liver cirrhosis. HIFU was also shown to be safe and 
effective to reduce the drop-out rate of liver transplant 
candidate[87]. 
LIveR TRaNspLaNTaTION
Liver transplantation treats HCC together with the 
underlying liver disease. The Milan criteria (single tumour 
≤ 5 cm, up to 3 tumours each ≤ 3 cm in diameter) is 
the gold standard for selection of deceased donor liver 
transplantation (DDLT). The disease-free survival at 4 
years for patients within the criteria was reported to be 
92%[88]. Many centres extended the criteria as evidence 
showed that patients outside the Milan criteria also have 
favourable outcomes after liver transplantation. In the 
west, the University of California, San Francisco criteria 
(single tumour ≤ 6.5 cm, up to 3 tumours at most 
with the largest ≤ 4.5 cm, and total diameter ≤ 8cm) 
had been shown with comparable outcome with Milan 
criteria[89]. Asian centres extended the HCC transplant 
criteria further because the majority of liver grafts were 
from living donor[90-93]. Living donor organ is considered a 
“gift” and there is less societal concern of equity[94]. 
In Asia, the organ donation rates remain the lowest 
worldwide[90]. As a result, living donor liver transplantation 
(LDLT) comprises the major workload and becomes an 
important treatment option for managing HCC in Asia. 
The overall survival rates were shown to be the same 
with studies comparing outcomes of DDLT and LDLT[95-99]. 
In view of the shortage of donated organ in Asia, 
multiple strategies had been developed, including using 
marginal livers, domino donors, and split liver transplant. 
Also bridging therapy with ablative and transarterial 
interventions aims to prevent tumour progression[100]. 
However, in survey up to 2005, 96% of liver transplant 
for HCC in Asian centers were from live donors[90]. 
TRaNsaRTeRIaL LOCORegIONaL 
TheRapy
TACE is the most widely used treatment for HCCs which 
are unresectable or cannot be effectively treated with 
percutaneous intervention for over 3 decades[54,101,102]. 
During the procedure, iodized poppy seed oil (lipiodol) 
and chemotherapeutic agents are administered through 
the feeding artery of the tumour, followed by arterial 
embolization. TACE results in delay tumour progression 
and vascular invasion and result in a survival benefit 
compared with conservative management. The most 
important aspect is the selection of patients, i.e., 
patients should have preserved liver function, with no 
portal vein thrombosis and extrahepatic spread. A meta-
analysis of six trials found a survival benefit for TACE 
over conservative management[101]. Two-year survival 
rates were reported as 31% vs 11% for conservative 
treatment[54]. TACE can be combined with other ablative 
therapies such as RFA[103,104]. 
The use of drug eluting bead (DEB) in TACE was 
reported in 2007[105,106] for its safety and efficacy. 
Microspheres composed of synthetic polymers or 
natural materials such as albumin, gelatine, chitosa or 
aliginate roughly fall into two categories - 15-60 μm and 
100-250 μm[107]. Drugs included doxorubicin, mitomycin 
C, cisplatin, etc., can be loaded to the beads[107]. 
DEBs have potential to simplify and standardize the 
TACE procedure by preloading the embolic with drug 
followed by controlled drug elution in target tissue[107]. 
A randomized controlled trial in 212 patients with HCC 
demonstrated that DEB-TACE is better tolerated than 
conventional lipiodol-based TACE, but this trial failed to 
demonstrate superiority in tumour response[108]. 
Transarterial radioembolization (TARE) using 
yttrium-90 microspheres can be used for patients with 
portal vein thrombosis[109-115]. Tumoricidal radiation doses 
are delivered with minimal toxicity to functional liver 
and there is minimal to moderate embolization (micro-
embolization) and minimal alteration in vascularity 
with TARE. Several authors have compared outcomes 
following TACE with TARE in matched patient cohorts, 
and reported comparable efficacy for TACE and TARE 
in terms of tumour response and overall survival[116-119]. 
However, randomized controlled trials comparing their 
efficacy with other therapies are lacking[120]. 
sysTemIC TheRapy
Systemic chemotherapy had a disappointing record 
in management of HCC[121]. With recent knowledge of 
hepato-carcinogenesis, there has been encouraging 
development in target therapy of advanced HCC. Sorafenib 
is an oral multikinase inhibitor that has activity against 
several serine/threonine kinases and tyrosine kinases. It 
was the first systemic therapy shown to prolong survival 
in patients with HCC, and is approved for use in advanced 
HCC[122]. The Sorafenib HCC Assessment Randomized 
Chu KKW et al . Update in management of HCC
1567 June 18, 2015|Volume 7|Issue 11|WJH|www.wjgnet.com
Protocol trial[123] is a large, placebo-controlled phase Ⅲ 
trial in patients with advanced HCC and preserved liver 
function (Child-Pugh class A). It demonstrated prolonged 
median survival for approximately 3 mo in sorafenib 
group. Cheng et al[124] in another study involving 271 Asian 
patients showed a 2 mo prolongation in survival in patients 
with advanced HCC. Many other novo agents were being 
investigated at the moment but it was only Sorafenib that 
has demonstrated the effect of providing significant longer 
overall survival.
CONCLUsION
Management of HCC has changed significantly over the 
past several decades. However, the management of 
patients has yet to be standardized. As a result of high 
prevalence of hepatitis B infection in Asia, the experience 
of the East helped to develop a more aggressive 
management algorithm. To ensure the most effective 
treatment to be offered for HCC patients, a good patient 
selection for the right modality need to be practised. 
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